{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:36:33Z","timestamp":1781537793247,"version":"3.54.5"},"publisher-location":"New York, NY","reference-count":19,"publisher":"Springer US","isbn-type":[{"value":"9781071627716","type":"print"},{"value":"9781071627723","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-2772-3_15","type":"book-chapter","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T18:07:03Z","timestamp":1668794823000},"page":"255-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular and Biochemical Assessment of Gene Therapy in the Canine Model of Duchenne Muscular Dystrophy"],"prefix":"10.1007","author":[{"given":"Chady H.","family":"Hakim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"P\u00e9rez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"issue":"1286","key":"15_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1098\/rspb.1989.0032","volume":"237","author":"LM Kunkel","year":"1989","unstructured":"Kunkel LM (1989) The Wellcome lecture, 1988. Muscular dystrophy: a time of hope. Proc R Soc Lond B Biol Sci 237(1286):1\u20139","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"15_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coviro.2016.07.006","volume":"21","author":"D Duan","year":"2016","unstructured":"Duan D (2016) Systemic delivery of adeno-associated viral vectors. Curr Opin Virol 21:16\u201325. https:\/\/doi.org\/10.1016\/j.coviro.2016.07.006","journal-title":"Curr Opin Virol"},{"issue":"10","key":"15_CR3","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan D (2018) Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol Ther 26(10):2337\u20132356. https:\/\/doi.org\/10.1016\/j.ymthe.2018.07.011","journal-title":"Mol Ther"},{"issue":"4","key":"15_CR4","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/mt.2012.283","volume":"21","author":"J-H Shin","year":"2013","unstructured":"Shin J-H, Pan X, Hakim CH et al (2013) Microdystrophin ameliorates muscular dystrophy in the canine model of Duchenne muscular dystrophy. Mol Ther 21(4):750\u2013757. https:\/\/doi.org\/10.1038\/mt.2012.283","journal-title":"Mol Ther"},{"issue":"20","key":"15_CR5","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.1093\/hmg\/ddv310","volume":"24","author":"Y Yue","year":"2015","unstructured":"Yue Y, Pan X, Hakim CH et al (2015) Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet 24(20):5880\u20135890","journal-title":"Hum Mol Genet"},{"key":"15_CR6","doi-asserted-by":"publisher","first-page":"16105","DOI":"10.1038\/ncomms16105","volume":"8","author":"C Le Guiner","year":"2017","unstructured":"Le Guiner C, Servais L, Montus M et al (2017) Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun 8:16105. https:\/\/doi.org\/10.1038\/ncomms16105","journal-title":"Nat Commun"},{"issue":"Suppl 1","key":"15_CR7","doi-asserted-by":"publisher","first-page":"S198","DOI":"10.1016\/S1525-0016(16)33308-1","volume":"24","author":"CH Hakim","year":"2016","unstructured":"Hakim CH, Pan X, Kodippili K et al (2016) Intravenous delivery of a novel micro-dystrophin vector prevented muscle deterioration in young adult canine Duchenne muscular dystrophy dogs. Mol Ther 24(Suppl 1):S198\u2013S199","journal-title":"Mol Ther"},{"issue":"S1","key":"15_CR8","first-page":"5","volume":"26","author":"CH Hakim","year":"2018","unstructured":"Hakim CH, Kodippili K, Jenkins G et al (2018) AAV micro-dystrophin therapy ameliorates muscular dystrophy in young adult Duchenne muscular dystrophy dogs for up to 30 months following injection. Mol Ther 26(S1):5","journal-title":"Mol Ther"},{"issue":"6","key":"15_CR9","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/sj.mt.6300161","volume":"15","author":"Z Wang","year":"2007","unstructured":"Wang Z, Kuhr CS, Allen JM et al (2007) Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 15(6):1160\u20131166","journal-title":"Mol Ther"},{"issue":"7","key":"15_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/hum.2018.012","volume":"29","author":"D Duan","year":"2018","unstructured":"Duan D (2018) Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients. Hum Gene Ther 29(7):733\u2013736. https:\/\/doi.org\/10.1089\/hum.2018.012","journal-title":"Hum Gene Ther"},{"key":"15_CR11","doi-asserted-by":"publisher","unstructured":"Mendell JR, Sahenk Z, Lehman K et al (2020) Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1484","DOI":"10.1001\/jamaneurol.2020.1484"},{"key":"15_CR12","unstructured":"Solid Biosciences (2021) solid biosciences reports efficacy and safety data from the ongoing IGNITE DMD clinical trial and resumption of patient dosing in the 2E14 vg\/kg cohort, March 15. https:\/\/investors.solidbio.com\/news-releases\/news-release-details\/solid-biosciences-reports-efficacy-and-safety-data-ongoing"},{"key":"15_CR13","unstructured":"Pfizer (2020) Pfizer\u2019s new phase 1b results of gene therapy in ambulatory boys with Duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 study, May 15. https:\/\/investors.pfizer.com\/investor-news\/press-release-details\/2020\/Pfizers-New-Phase-1b-Results-of-Gene-Therapy-in-Ambulatory-Boys-with-Duchenne-Muscular-Dystrophy-DMD-Support-Advancement-into-Pivotal-Phase-3-Study\/default.aspx"},{"issue":"6410","key":"15_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","volume":"362","author":"L Amoasii","year":"2018","unstructured":"Amoasii L, Hildyard JCW, Li H et al (2018) Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science 362(6410):86\u201391. https:\/\/doi.org\/10.1126\/science.aau1549","journal-title":"Science"},{"issue":"1","key":"15_CR15","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.1038\/s41467-021-26830-7","volume":"12","author":"CH Hakim","year":"2021","unstructured":"Hakim CH, Kumar SRP, Perez-Lopez DO et al (2021) Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nat Commun 12(1):6769. https:\/\/doi.org\/10.1038\/s41467-021-26830-7","journal-title":"Nat Commun"},{"issue":"3","key":"15_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1590\/S1415-47572002000300011","volume":"25","author":"FH Biase","year":"2002","unstructured":"Biase FH, Franco MM, Goulart LR et al (2002) Protocol for extraction of genomic DNA from swine solid tissues. Genet Mol Biol 25(3):313\u2013315","journal-title":"Genet Mol Biol"},{"issue":"2","key":"15_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088280","volume":"9","author":"K Kodippili","year":"2014","unstructured":"Kodippili K, Vince L, Shin JH et al (2014) Characterization of 65 epitope-specific dystrophin monoclonal antibodies in canine and murine models of Duchenne muscular dystrophy by immunostaining and western blot. PLoS One 9(2):e88280. https:\/\/doi.org\/10.1371\/journal.pone.0088280","journal-title":"PLoS One"},{"issue":"23","key":"15_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124297","volume":"3","author":"CH Hakim","year":"2018","unstructured":"Hakim CH, Wasala NB, Nelson CE et al (2018) AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice. JCI Insight 3(23):124297. https:\/\/doi.org\/10.1172\/jci.insight.124297","journal-title":"JCI Insight"},{"key":"15_CR19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.omtm.2020.07.004","volume":"18","author":"CH Hakim","year":"2020","unstructured":"Hakim CH, Clement N, Wasala LP et al (2020) Micro-dystrophin AAV vectors made by transient transfection and herpesvirus system are equally potent in treating mdx mouse muscle disease. Mol Ther Methods Clin. ev 18:664\u2013678. https:\/\/doi.org\/10.1016\/j.omtm.2020.07.004","journal-title":"Mol Ther Methods Clin. ev"}],"container-title":["Methods in Molecular Biology","Muscular Dystrophy Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2772-3_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T07:07:47Z","timestamp":1677654467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2772-3_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"ISBN":["9781071627716","9781071627723"],"references-count":19,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2772-3_15","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"19 November 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}